{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T19:29:04Z","timestamp":1771010944316,"version":"3.50.1"},"reference-count":9,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2014,11,8]],"date-time":"2014-11-08T00:00:00Z","timestamp":1415404800000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Development Research"],"published-print":{"date-parts":[[2014,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:table-wrap position=\"anchor\">\n\n<jats:table frame=\"hsides\">\n<jats:col\/>\n<jats:tbody>\n<jats:tr>\n<jats:td>Postmarketing Phase IV<\/jats:td>\n<\/jats:tr>\n<\/jats:tbody>\n<\/jats:table>\n\n<\/jats:table-wrap><\/jats:p><jats:p>Tumor necrosis factor (<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>) inhibitor therapies (anti\u2010<jats:styled-content style=\"fixed-case\">TNFs<\/jats:styled-content>) are used routinely as first\u2010line biotherapy for the treatment of rheumatoid arthritis (<jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content>) and spondyloarthritis (<jats:styled-content style=\"fixed-case\">SpA<\/jats:styled-content>: psoriatic arthritis [<jats:styled-content style=\"fixed-case\">PsA<\/jats:styled-content>] and ankylosing spondylitis [<jats:styled-content style=\"fixed-case\">AS<\/jats:styled-content>]) in patients who have failed traditional non\u2010biologic disease\u2010modifying anti\u2010rheumatic drugs (<jats:styled-content style=\"fixed-case\">DMARDs<\/jats:styled-content>). However, about 30% of patients experience failure of first\u2010line anti\u2010<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content> agent because of inefficacy or adverse events. This study analyzed long\u2010term anti\u2010<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>\u03b1 drug survival in a clinical practice setting. The overall 10\u2010year retention rate of first\u2010line anti\u2010<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content> agent is about 23%, being significantly higher for <jats:styled-content style=\"fixed-case\">SpA<\/jats:styled-content> compared with <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content> patients. <jats:styled-content style=\"fixed-case\">ETN<\/jats:styled-content> is the most persistent anti\u2010<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content> with a drug survival rate significantly higher than <jats:styled-content style=\"fixed-case\">IFX<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">ADA<\/jats:styled-content>.<\/jats:p>","DOI":"10.1002\/ddr.21192","type":"journal-article","created":{"date-parts":[[2014,11,8]],"date-time":"2014-11-08T08:02:04Z","timestamp":1415433724000},"source":"Crossref","is-referenced-by-count":28,"title":["Ten\u2010Year Drug Survival of Anti\u2010<scp>TNF<\/scp> Agents in the Treatment of Inflammatory Arthritides"],"prefix":"10.1002","volume":"75","author":[{"given":"Martina","family":"Biggioggero","sequence":"first","affiliation":[{"name":"Department of Rheumatology Gaetano Pini Institute  Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ennio Giulio","family":"Favalli","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Gaetano Pini Institute  Milan Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,11,8]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar1941"},{"key":"e_1_2_6_3_1","first-page":"2433","article-title":"Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients","volume":"33","author":"Duclos M","year":"2006","journal-title":"J Rheumatol"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2013.07.011"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar1881"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.27227"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22331"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.111125"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2009.04621.x"},{"key":"e_1_2_6_10_1","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007848","article-title":"Biologics for rheumatoid arthritis: an overview of Cochrane reviews","volume":"4","author":"Singh JA","year":"2009","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Drug Development Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fddr.21192","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ddr.21192","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T08:59:23Z","timestamp":1760345963000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/ddr.21192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":9,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["10.1002\/ddr.21192"],"URL":"https:\/\/doi.org\/10.1002\/ddr.21192","archive":["Portico"],"relation":{},"ISSN":["0272-4391","1098-2299"],"issn-type":[{"value":"0272-4391","type":"print"},{"value":"1098-2299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11]]}}}